tiprankstipranks
Verve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101
PremiumThe FlyVerve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101
24d ago
Verve Therapeutics pauses enrollment in Heart-1 trial of VERVE-101
PremiumThe Fly
Verve Therapeutics pauses enrollment in Heart-1 trial of VERVE-101
24d ago
Verve Therapeutics Announces Updates on its PCSK9 Program
PremiumPress Releases
Verve Therapeutics Announces Updates on its PCSK9 Program
24d ago
Verve Therapeutics reports Q4 EPS (69c), consensus (82c)
PremiumThe FlyVerve Therapeutics reports Q4 EPS (69c), consensus (82c)
2M ago
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PremiumPress Releases
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
3M ago
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress Releases
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
4M ago
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
PremiumPress ReleasesVerve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
5M ago
Verve Therapeutics announces common stock offering, concurrent private placement
PremiumThe Fly
Verve Therapeutics announces common stock offering, concurrent private placement
5M ago
Verve Therapeutics falls 37% after adverse events in VERVE-101 study
PremiumThe Fly
Verve Therapeutics falls 37% after adverse events in VERVE-101 study
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100